Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA
Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...
Pharm Exec2d
FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Kepler Capital Sticks to Their Buy Rating for MedinCell SA (MEDCL)
Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on MedinCell SA (MEDCL – Research Report) on February 26 and set a price ...
FDA accepts Teva & Medincell’s UZEDY sNDA for extended-release to treat BP-I
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
The Pharma Letter2d
FDA accepts Teva and Medincell’s Uzedy sNDA
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...
Morningstar2d
Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA
Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live ...
Pharmabiz1d
Teva Pharma, Medincell announce US FDA acceptance of sNDA for Uzedy to treat people living with schizophrenia
Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...
Investing3d
FDA accepts Teva, Medincell’s supplemental application for UZEDY as bipolar I disorder treatment
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...
Morningstar10d
Medincell Launches a Global Offering for Approximately 10% of Its Share Capital
Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO® technology’s reach into new molecules and indications, and potentially by potentially considering ...
Yahoo Finance10d
Medincell Launches a Global Offering for Approximately 10% of Its Share Capital
The Global Offering is also aimed at retail investors via PrimaryBid platform, exclusively in France. Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO ® ...